Therefore, a more accurate study on FoxO3a protein expression by means of IHC of tissue microarrays (TMA), or even proteomics, in all the different BC subtypes is mandatory, in order to rule out the significance of FoxO3a as a predictive marker when associated (or not) with other prognostic factors. Here, FOXO3 is linked to breast cancer.